This is an erratum correcting a typographical error in a consensus statement on SGLT-2 inhibitors and GLP-1 receptor agonists.
Clinicians should reference the corrected macroalbuminuria terminology for accurate SGLT2i/GLP-1RA guidance; erratum upholds precision of level-1 consensus recommendations.
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA, Nephrology Dialysis Transplantation 2019; gfy407. doi: 10.1093/ndt/gfy407 In the original article, the words ‘micro- or microalbuminuria’ should have read ‘micro- or macroalbuminuria’ in the top boxes of Figures 4 and 5. doi: 10.1093/ndt/gfz137
No takes yet. Share an insight, caveat, or question.
Sarafidis et al. (2019) studied Diabetes mellitus and chronic kidney disease. SGLT-2 inhibitors and GLP-1 receptor agonists was evaluated. An erratum was published to correct 'micro- or microalbuminuria' to 'micro- or macroalbuminuria' in Figures 4 and 5 of the original consensus statement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: